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selection bias between groups. Administrative claims and
medical records were utilized to assign patients NCEP risk status
and corresponding LDL-C goal. Percent changes in lipid values
were computed by comparing pre/post-initiation levels. Adjusted
LDL-C change and goal attainment were evaluated using OLS
and logistic regression techniques, respectively. RESULTS: A
total of 453 patients (217 rosuvastatin/236 atorvastatin) were
identiﬁed. Mean dose and therapy duration for rosuvastatin were
11mg and 61 days compared to 15mg and 79 days for atorvas-
tatin. Patients receiving rosuvastatin compared to atorvastatin
had signiﬁcantly greater mean percent reductions in LDL-C
(35% vs. 26%), total cholesterol (26% vs. 20%), and non HDL-
C (33% vs. 25%); all p < 0.05. After adjusting for age, gender,
baseline LDL-C, NCEP risk status, and therapy duration, reduc-
tions in percent LDL-C continued to be statistically signiﬁcant.
No statistically signiﬁcant differences were found in HDL-C and
triglycerides between groups. Percentages of patients achieving
their LDL-C goal with rosuvastatin and atorvastatin were 74%
and 65%, respectively. After adjusting for baseline differences
between groups, signiﬁcantly (p < 0.05) more patients were
observed to achieve their LDL-C goal with rosuvastatin (OR =
1.87, 95% CI: 1.10–3.17). CONCLUSION: Rosuvastatin was
associated with statistically signiﬁcant reductions in LDL-C, non
HDL-C, and total cholesterol compared to atorvastatin. Fur-
thermore, rosuvastatin patients were nearly twice as likely to
attain their LDL-C goal compared with atorvastatin when
adjusted for baseline differences between groups.
CV3
ONE-YEAR COSTS FOR ACUTE CORONARY SYNDROME—
AN INTEGRATED HEALTHCARE SYSTEM PERSPECTIVE
Sidney S1, Sorel M1, Quesenberry Jr CP1, McCollam PL2
1Kaiser Permanente, Oakland, CA, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA
OBJECTIVES: Little information exists regarding costs of acute
coronary syndrome (ACS) in the setting of an integrated health
care program. The purpose of this study was to estimate total
costs of new onset ACS from index hospitalization through one
year. METHODS: This descriptive analysis consisted of Kaiser
Permanente Medical Care Program patients age > 40 years and
hospitalized with an ACS diagnosis during January 1, 1999 to
December 31, 2000. Patients were required to be without ACS
diagnoses in the six months before the index event. Follow-up
continued for one year. A gender and age matched control group
was created at a 5 :1 ratio (control :ACS patient). Costs expressed
are those incurred by the health plan. RESULTS: In total, 14,852
patients met inclusion criteria (7919 myocardial infarction [MI],
6933 unstable angina [UA]). Mean age was 67.2 years, and 
63.9% were male. During the ﬁrst year after the index event,
rehospitalization occurred in 13.5% of patients for MI, 17.2%
for UA, and 38.5% for all coronary heart disease. Index hospi-
talization costs were $6802 for ACS cases. Total costs (mean ±
SD) from discharge through one year were $20,743 ± 30,159
($12,163 median) for ACS cases and $3679 ± 12,495 ($1089
median) for controls. Males and females with ACS had similar
mean costs ($20,894 ± 31,179 vs. $20,475 ± 28,262) while ACS
cases age >65 ($21,354 ± 27,904) had somewhat higher mean
costs than those age <65 years ($19,862 ± 33,126). Percent of
total costs by type of resource used (clinic, hospital, and phar-
macy, respectively) for ACS cases was: 19.4%, 70.3%, 6.2%; for
controls: 38.4%, 43.5%, 13.0%. CONCLUSIONS: Hospitaliza-
tion for ACS was associated with substantial costs for the index
event as well as large additional costs through one year. The
largest contributor of costs was hospital-related (70%). Rehos-
pitalization also occurred frequently in ACS patients.
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OBJECTIVES: Little is known about the association of length of
exposure to COX-2 inhibitors (COX-2s) and the risk of cardiac
events. This study determines the impact of extended exposure
to COX-2s among high risk Medicaid patients, and is based on
a previous propensity adjusted model that showed no added risk
of cardiac events in COX-2 versus NSAID users, in this Medic-
aid population. METHODS: Selecting COX-2 users alone, we
analyzed all medical and prescription claims of all continuously
enrolled Medicaid patients, with at least one prescription for a
COX-2 between January 1, 2000 and January 1, 2003, and no
such prescriptions in the ﬁrst six months. We used both direct
adjustment and propensity score methods, and assessed length
of exposure to COX-2s as a risk factor for post-use cardiac
events, deﬁning risk as a categorical variable (<30, 30–59,
60–89, 90–119 and >120 days), then as a continuous variable
(divided by 30). The models are adjusted for age, gender, race
and location (urban/suburban/rural), and clinical risk factors.
RESULTS: A total of 1784 patient used COX-2s, 25% for less
than 30 days. From the categorical analysis, there are signiﬁcant
increases in the likelihood of a post-use cardiac event given
increased use compared to less than 30 days of cumulative 
exposure. From the analysis of exposure to COX-2s as a con-
tinuous variable, in the propensity-adjusted model, each 30-day
increase in exposure corresponds to a concomitant but non-
signiﬁcant 2% increase in risk of cardiac events. For the 
direct adjusted model, there is a concomitant 5.5%, signiﬁcant
increase in post-use cardiac events. CONCLUSIONS: Among
Medicaid COX-2 users, the risk of cardiac events is associated
with longer exposure to COX-2s only when exposure is catego-
rized in 30-days increments, but not when used as a continuous
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OBJECTIVE: For women over age 45 that experience osteo-
porosis-related fractures (OPFx), Medicaid covers about 25%
while Medicare covers nearly one-half of the related-health care
cost. This study estimated the direct cost of OPFx to state Med-
icaid budgets. METHODS: This retrospective analysis utilized
Medicaid claims databases from three states. The databases 
contained the claims experience of approximately eight million
Medicaid recipients. The study sample consisted of Medicaid
beneﬁciaries with at least one claim containing an osteoporosis
diagnosis (733.0x) between January 1, 1999 and December 31,
2001. Beneﬁciaries with a fracture and a diagnosis of osteo-
porosis were assigned to the case cohort; a propensity score-
based matching method was used to select a cohort of controls
among a pool of beneﬁciaries with osteoporosis, but without a
fracture. An exponential conditional mean model was used to
estimate the incremental annual cost associated with fracture.
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RESULTS: The OPFx cohort (n = 7626) and a 1 :1 matched
control group with osteoporosis, but without a fracture were
identiﬁed. The OPFx cohort was 85.8% female, had an average
age of 65, were 53.2% White and 11.1% Asian, and 48.9% were
dual-eligible for Medicare. There were signiﬁcant increases (all
p < 0.05) from the pre-period to study-period for this cohort in
the proportion that had at least one hospital admission (12.0%
vs. 22.3%), nursing home admission (8.7% vs. 18.2%) or ER
visit (28.2% vs. 45.9%); in contrast, the control cohort had very
little variation in utilization. The regression-adjusted incremen-
tal cost in the year following fracture was estimated at $4007
per osteoporosis patient. The estimated incremental cost was
$5370 for the subset of patients who were dual-eligible. CON-
CLUSIONS: Osteoporosis-related fractures exhibit a tremen-
dous humanistic and economic toll in patients. The economic
burden of OPFx on state Medicaid budgets is substantial. Pre-
ventative strategies for avoiding fractures could help ameliorate
some of this burden.
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OBJECTIVES: To estimate impact of cardiovascular events on
annual health care costs in newly diagnosed type-2 diabetes
patients. METHODS: Patients with newly diagnosed type-2 dia-
betes (index event) between January, 1999 and December, 2001
were identiﬁed from an employer claims database using ICD-9
codes. In the absence of a diagnosis, patients were included 
if they had at least two claims for oral hypoglycemics in a 
six-month period. A cardiovascular event was deﬁned as emer-
gency/inpatient claims for one or more of 16 cardiovascular com-
plications identiﬁed. Patients with evidence of a cardiovascular
event in the 12 months preceding the index event were excluded.
Costs were adjusted to 2002 dollars and then annualized. A log-
transformed model was developed to estimate the impact of 
cardiovascular events on annual health care costs. Patient 
demographics, co-morbidities, concomitant medications and
treatment groups were used as covariates. RESULTS: Based on
the selection criteria, the study cohort included 57,563 newly
diagnosed type-2 diabetes patients. The average patient age was
59.5 years and 50.7% were female. The mean adjusted annual
health care cost per patient was $11,994.33. Annual cost was
distributed across emergency room (2.49%), outpatient (45%),
inpatient (29.75%) and prescription drug (22.54%) costs.
Annual costs were signiﬁcantly greater in women (17.1%; p <
0.001) and signiﬁcantly lower in absence of any complications
(-14.5%; p < 0.001). About 12% of the type-2 diabetes patient
population reported one or more cardiovascular events. The
mean number of cardiovascular events per patient per year 
was 0.067. A cardiovascular event contributed to a signiﬁcant
increase (129%; p < 0.001) in annual costs. The average annual
cost per patient ranged from $9,507 (zero CV event) to $65,130
(5+ CV events). CONCLUSIONS: Cardiovascular events con-
tribute signiﬁcantly to health care costs in the type-2 diabetes
patients.
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OBJECTIVE: To evaluate the sensitivity of overactive bladder
(OAB) medical cost estimates to estimation technique.
METHODS: Data were from de-identiﬁed medical and phar-
macy claims of patients aged ≥18 years enrolled in a large US
health plan. Inclusion criteria were: ≥1 claim with OAB-related
ICD-9-CM codes recorded between January 1, 2001 and Decem-
ber 31, 2002; initiation of immediate-release oxybutynin (OXY
IR), extended-release OXY (OXY ER), or extended-release
tolterodine (TOL ER); and continuous health plan coverage 
for six months before and 12 months after treatment initiation.
Models were based on logged 12-month medical costs, with
treatment, sex, age, geographic region, baseline costs, and
comorbidities as covariates. Estimation techniques compared
were ordinary least squares (OLS) with smearing estimator, treat-
ment regressions estimating the correlation between cost and
treatment, and two-stage instrumental variables (IV) regressions.
Selectivity-corrected models were estimated for OXY IR and
OXY ER, with TOL ER as the referent. RESULTS: Association
of treatment with cost varied with estimation technique. Com-
paring costs of TOL ER and OXY ER, coefﬁcients were OLS,
0.582 (t = 1.86, p = 0.063); treatment regression, 1.108 (Z =
3.93, p < 0.001); IV regression, 1.878 (Z = 3.27, p = 0.001). A
negative correlation between treatment and cost (p, -0.3842, 
p < 0.001) suggested that OLS estimates underestimated cost 
differences between TOL ER and OXY ER therapies. OXY ER
patients had one-year predicted medical costs 191% higher
(treatment regression) or 455% higher (IV regressions) than 
did TOL ER patients. The treatment regression correlation
between the TOL ER and OXY IR treatment groups was sig-
niﬁcant and negative, suggesting that OLS also underestimated
differences in cost between those cohorts. Treatment regression
analysis revealed that costs for OXY IR patients were 48%
higher than those for TOL ER patients. CONCLUSIONS:
Failing to adjust for selection bias when comparing OAB treat-
ment costs may lead to biased estimates of cost differences
between therapies.
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OBJECTIVE: Atrial ﬂutter (AFL) is a prevalent arrhythmia
among the elderly. While numerous clinical studies have shown
the safety and efﬁcacy of cardiac ablation, the ﬁrst-line approach
still varies among physicians. The study objective is to assess the
cost-utility of catheter ablation as ﬁrst-line treatment of typical
isthmus dependent AFL. METHODS: The incremental cost-
effectiveness of catheter ablation relative to cardioversion and
drug therapy was analyzed over various time horizons up to ﬁve
years using a decision analytic Markov model (DATA 4.0TM,
TreeAge Software Inc.). Costs were based on a third party payer’s
perspective using 2004 Medicare reimbursement schedules and
discounted average wholesale drug prices. Model parameters,
adverse event rates, and utility weight estimates were obtained
from published clinical trials. Costs and utilities were discounted
at 3% annually and sensitivity analyses were performed. The
model analyzed the outcomes and resource utilization of a hypo-
thetical cohort of patients with typical isthmus-dependent AFL.
RESULTS: Ablation consistently produced greater quality-
adjusted life years (QALYs) compared to cardioversion and
drugs in analyses of one to ﬁve years (0.78 to 3.57 vs. 0.66 to
2.93 QALYs). While initial treatment costs are higher for abla-
tion compared to cardioversion and drug therapy, ablation
